^
Association details:
| Biomarker: | BRAF G469A |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
BioMed Valley Discoveries’ ulixertinib (BVD-523), a first-in-class ERK inhibitor cancer therapy, receives Fast Track designation and launches Phase II trial in collaboration with Cmed and Strata Oncology
Published date:
07/29/2020
Excerpt:
BioMed Valley Discoveries (BVD), a clinical stage biotechnology company, announces the receipt of Fast Track designation from the US Food and Drug Administration (FDA) for investigation of the ERK inhibitor ulixertinib (BVD-523) as a treatment for patients with non-colorectal, solid tumors that harbor BRAF mutations G469A/V, L485W, or L597Q.
